Revolve Wealth Partners LLC Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 8.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,490 shares of the company’s stock after purchasing an additional 200 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $214,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the 3rd quarter worth about $28,000. Capital Performance Advisors LLP purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $42,000. Carolina Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. Finally, M&R Capital Management Inc. boosted its stake in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after purchasing an additional 297 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 2.9 %

Novo Nordisk A/S stock opened at $85.00 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market cap of $381.45 billion, a PE ratio of 27.51, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The stock has a 50-day moving average of $95.10 and a two-hundred day moving average of $114.43. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.